A non-Smad mechanism of fibroblast activation by transforming growth factor-β via c-Abl and Egr-1: Selective modulation by imatinib mesylate

Oncogene

Volumn 28, Issue 10, 2009, Pages 1285-1297

  Bhattacharyya, S ^a   Ishida, W ^a   Wu, M ^a   Wilkes, M ^b   Mori, Y ^a   Hinchcliff, M ^a   Leof, E ^b   Varga, J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

c Abl; Egr 1; Fibroblast; Fibrosis; Imatinib mesylate; TGF

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ABELSON KINASE; BCR ABL PROTEIN; BLEOMYCIN; COLLAGEN; EARLY GROWTH RESPONSE FACTOR 1; IMATINIB; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN 3T3; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; FEMALE; FIBROGENESIS; FIBROSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS;

ANIMALS; BLEOMYCIN; CELLS, CULTURED; COLLAGEN; EARLY GROWTH RESPONSE PROTEIN 1; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; FIBROSIS; HUMANS; MICE; MICE, INBRED BALB C; NIH 3T3 CELLS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

MUS;

EID: 62249183044     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.479     Document Type: Article

References (63)

1. Bhattacharyya S, Chen S-J, Wu M, Warner-Blankenship M, Ning H, Lakos G et al. (2008). Smad-independent TGF-β regulation of transcription factor Egr-1 and sustained expression in fibrosis: implications for scleroderma. Am J Path 173: 1085-1099.
2. Buchwalter G, Gross C, Wasylyk B. (2004). Ets ternary complex transcription factors. Gene 324: 1-14.
3. Bonner JC. (2004). Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth factor Rev 4: 255-273.
4. 2-mediated c-Abl activation in human hepatic stellate cells. Gastroenterology 131: 1235-1252.
5. Che W, Abe J, Yoshizumi M, Huang Q, Glassman M, Ohta S et al. (2001). p160 Bcr mediates platelet-derived growth factor activation of extracellular signal-regulated kinase in vascular smooth muscle cells. Circulation 104: 1399-1406.
6. Chen SJ, Ning H, Ishida W, Sodin-Semrl S, Takagawa S, Mori Y et al. (2006). The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 281: 21183-21197.
7. Chen SJ, Yuan W, Mori Y, Levenson A, Trojanowska M, Varga J. (1999). Stimulation of Type I collagen transcription in human skin fibroblasts by TGF-β: involvement of Smad 3. J of Invest Dermatol 112: 49-57.
8. Danial NN, Rothman P. (2000). JAK-STAT signaling activated by Abl oncogenes. Oncogene 19: 2523-2531.
9. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH et al. (2004). Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114: 1308-1316.
10. Deininger MW, Goldman JM, Lydon N, Melo JV. (1997). The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90: 3691-3698.
11. Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE et al. (2007). Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56: 311-322.
12. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566.
13. Gashler A, Sukhatme VP. (1995). Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Prog Nucleic Acid Res Mol Biol 50: 191-224.
14. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. (1984). Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome. Cell 36: 93-99.
15. Goldman JM, Melo JV. (2003). Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 349: 1451-1464.
16. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. (2002). Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 21: 1743-1753.
17. He X. (2006). Unwinding a Path to Nuclear β-Catenin. Cell 127: 40-42.
18. Hernández SE, Krishnaswami M, Miller AL, Koleske AJ. (2004). How do Abl family kinases regulate cell shape and movement? Review Trends Cell Biol 14: 36-44.
19. Ihn H, LeRoy EC, Trojanowska M. (1997). Oncostatin M stimulates transcription of the human α2 (I) collagen gene via the Sp1/Sp3-binding site. J Biol Chem 272: 24666-24672.
20. Ishida W, Bhattacharyya S, Hinchcliff M, Mori Y, Takehara K, Varga J. (2006). Novel role of c-Abl tyrosine kinase in profibrotic TGF-Beta responses: Selective modulation by the anticancer drug imatinib methylate (gleevec). Arthritis Rheum 54: S776.
21. Javelaud D, Mauviel A. (2005). Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 24: 5742-5750.
22. Jimenez SA, Derk CT. (2004). Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 140: 37-45.
23. Khachigian LM. (2006). Early growth response-1 in cardiovascular pathobiology. Circ Res 98: 186-191.
24. Kharbanda SP, Pandey S, Jin S, Inoue A, Bharti Z-M, Yuan R et al. (1997). Functional interaction of DNA-PK and c-Abl in response to DNA damage. Nature 386: 732-735.
25. Kharbanda SP, Pandey R, Ren S, Feller B, Mayer L, Zon et al. (1995a). c-Abl activation regulates induction of the SEK1/stress activated protein kinase pathway in the cellular response to 1-β-D- arabinofuranosylcytosine. J Biol Chem 270: 30278-30281.
26. Kharbanda SR, Ren P, Pandey TD, Shafman SM, Feller RR, Weichselbaum et al. (1995b). Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 376: 785-788.
27. Kharas MG, Fruman DA. (2005). ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 65: 2047-2053.
28. Lakos G, Takagawa S, Chen SJ, Ferreira AM, Han G, Masuda K et al. (2004). Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 165: 203-217.
29. La Rosée P, Johnson K, O'Dwyer ME, Druker BJ. (2002). In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 30: 729-737.
30. Lewis JM, Baskaran R, Taagepera S, Schwartz MA, Wang JY. (1996). Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci U S A 93: 15174 -15179.
31. Lewis JM, Schwartz MA. (1998). Integrins regulate the association and phosphorylation of paxillin by c-Abl. J Biol Chem 273: 14225-14230.
32. Leask A. (2008). Targeting the TGFb, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cellular Signalling 20: 1409-1414.
33. Lugo TG, Pendergast AM, Muller AJ, Witte ON. (1990). Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079-1082.
34. MassaguéJ, Seoane J, Wotton D. (2005). Smad transcription factors. Genes Dev 19: 2783-2810.
35. Mori Y, Chen SJ, Varga J. (2000). Modulation of endogenous Smad expression in normal skin fibroblasts by transforming growth factorbeta. Exp Cell Res 258: 374-383.
36. Mori Y, Ishida W, Bhattacharyya S, Li Y, Platanias LC, Varga J. (2004). Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis Rheum 50: 4008-4021.
37. Moustakas A, Heldin CH: Non-Javelaud D, Mauviel. (2005). A Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 24: 5742-5750.
38. Pannu J, Asano Y, Nakerakanti S, Smith E, Jablonska S, Blaszczyk M et al. (2008). Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum 58: 2528-2537.
39. Pannu J, Nakerakanti S, Smith E, ten Dijke P, Trojanowska M. (2007). Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem 282: 10405-10413.
40. Pannu J, Trojanowska M. (2004). Recent advances in fibroblast signaling and biology in scleroderma. Curr Opin Rheumatology 6: 739-745.
41. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. (1995). The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA 92: 11746-11755.
42. Rajkumar VS, Shiwen X, Bostrom M, Leoni P, Muddle J, Ivarsson M et al. (2006). Platelet-derived growth factor-β receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am J Pathol 169: 2254-2265.
43. Renshawa MW, Lewisa JM, Schwartz MA. (2000). The c-Abl tyrosine kinase contributes to the transient activation of MAP kinase in cells plated on fibronectin. Oncogene 19: 3216-3219.
44. Rosenbloom J, Jiménez SA. (2008). Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis. Arthritis Rheum 58: 2219-2224.
45. Rowley JD. (1973). Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290-293.
46. Sánchez-Arévalo Lobo VJ, Aceves Luquero CI, Alvarez-Vallina L, Tipping AJ, Viniegra JG, Hernández Losa J. (2005). Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. Biochem J 387: 231-238.
47. Schubert C, Schalk-Hihi C, Struble GT, Ma HC, Petrounia IP, Brandt B et al. (2007). Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors. J Biol Chem 282: 4094-4101.
48. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK et al. (1997). Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 16: 6151-6161.
49. Sukhatme VP, Cao XM, Chang LC, Tsai-Morris CH, Stamenkovich D, Ferreira PC et al. (1988). A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell 53: 37-43.
50. Stuart JR, Kawai H, Tsai KK, Chuang EY, Yuan ZM. (2005). c-Abl regulates early growth response protein (EGR1) in response to oxidative stress. Oncogene 24: 8085-8092.
51. Svaren J, Ehrig T, Abdulkadir SA, Ehrengruber MU, Watson MA, Milbrandt J. (2000). EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J Biol Chem 275: 38524-38531.
52. Takagawa S, Lakos G, Mori Y, Yamamoto T, Nishioka K, Varga J. (2003). Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma. J Invest Dermatol 121: 41-50.
53. Takahashi T, Abe H, Arai H, Matsubara T, Nagai K, Matsuura M et al. (2005). Activation of STAT3/Smad1 is a key signaling pathway for progression to glomerulosclerosis in experimental glomerulonephritis. J Biol Chem 280: 7100-7106.
54. Teckchandani AM, Feshchenko EA, Tsygankov AY. (2001). c-Abl facilitates fibronectin matrix production by v-Abl-transformed NIH3T3 cells via activation of small GTPases. Oncogene 20: 1739-1755.
55. Varga J, Abraham D. (2007). Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117: 557-567.
56. Varga JA, Trojanowska M. 2008)). Fibrosis in systemic sclerosis. Rheum Dis Clin North Am 34: 115-143.
57. Van Etten RA. (1999). Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol 9: 179-186.
58. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T et al. (2001). The Egr-1 transcription factor directly activates PTEN during irradiation-induced signaling. Nat Cell Biol 3: 1124-1128.
59. Wang S, Wilkes MC, Leof EB, Hirschberg R. (2005). Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 19: 1-11.
60. Wenner CE, Yan S. (2003). Biphasic role of TGF-beta1 in signal transduction and crosstalk. J Cell Physiol 196: 42-50.
61. Wilkes MC, Leof EB. (2006). Transforming growth factor beta activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures. J Biol Chem 281: 27846-27854.
62. Woodring PJ, Litwack ED, O'Leary DD, Lucero GR, Wang JY, Hunter T. (2002). Modulation of the Factin cytoskeleton by c-Abl tyrosine kinase in cell spreading and neurite extension. J Cell Biol 156: 879-892.
63. Yoshida K, Weichselbaum R, Kharbanda S, Kufe D. (2000). Role for Lyn tyrosine kinase as a regulator of stress-activated protein kinase activity in response to DNA damage. Mol Cell Biol 20: 5370-5380.